Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Bioscns (NQ: APTO )

0.1696 -0.0744 (-30.49%)
Streaming Delayed Price Updated: 1:27 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Bioscns

< Previous 1 2 3 4 5 Next >
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: Aptose Biosciences Q4 Earnings
Via Benzinga
Aptose Biosciences's Earnings: A Preview
Via Benzinga
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024! 
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
Why Is SU Group (SUGP) Stock Moving Today?
SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.